Navigation Links
Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
Date:9/5/2013

ANAHEIM, Calif., Sept. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will host investor meetings and will be a participant in a fireside chat session at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013 at 4:40 PM ET/1:40 PM PT. The Conference does not accommodate formal presentations or the use of slides so there will not be a webcast presentation.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following approved indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases".  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
Breaking Medicine Technology:
(Date:5/1/2016)... Aliso Viejo, CA (PRWEB) , ... May 01, 2016 , ... ProBrand Reveal Volume 2 ... Pro X . With ProBrand Reveal Volume 2 keyframeless animations, users can easily create a ... over the look and feel of the various presets. Use these title presets to add ...
(Date:4/30/2016)... ... April 30, 2016 , ... Powerful tools ... Hypnotherapist, Mary O'Maley. What is hypnosis and hypnotherapy and why after centuries, ... control), pain relief (chronic and acute), birthing processes and medical procedures, depression, anxiety, ...
(Date:4/30/2016)... ... ... of us, but there are things we can do to improve the odds of staying healthy ... more that there are simple, yet important steps that can be taken to maintain good health ... for her patients include;, , exercise , healthy diet ...
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... our nation’s productivity, stability, even security. Most importantly, employees are the single most ... why are American workers so unhappy? , Just under half of American workers ...
Breaking Medicine News(10 mins):